Entrada Therapeutics’ shares fell sharply after early Duchenne muscular dystrophy data for ENTR-601-44 fell short of expectations on dystrophin production. The Phase 1/2 results in exon 44-skipping patients showed favorable safety and tolerability, with indications for improved time-to-rise versus placebo, but investors focused on the magnitude of dystrophin increase. In the reported cohort, dystrophin production rose 2.36%, below analyst expectations of 10% or more. The market reaction suggests the company may need higher dosing strategies to compete with next-generation exon-skipping therapies and to close the performance gap. The therapy is designed to “skip” exon 44 in a subset of Duchenne patients, with development history shaped by prior regulatory holds, including an FDA pause on US trial initiation that lasted until February 2025. The episode also highlights the crowded exon-skipping landscape—where prior programs such as Avidity’s del-zota (approved pathway discussed after higher dystrophin production) continue to set benchmarks for both protein target engagement and eventual regulatory positioning.